University of Utah partners with Abundance Institute to boost innovation efforts
SALT LAKE CITY, March 24, 2025 /PRNewswire/ -- The University of Utah has formed a groundbreaking alliance with the Abundance Institute, a nonprofit that is focused on tackling societal and policy barriers facing emerging technologies. The U announced its partnership with the Institute as part of increased efforts to amplify its societal impact, especially through research and innovation.
'Some of our greatest modern-day advancements originate in university classrooms and labs — especially at the U,' President Taylor Randall said. 'This partnership will provide an opportunity to walk the path from idea to creation in a more collaborative way, bringing along inventors, regulators, legislators, and investors.'
Through this collaboration, the U and the institute will work with academic thought leaders, policymakers, and innovators to provide expert guidance on barriers that prevent new technologies from coming to market. They'll also share knowledge about the true risks and rewards of new technological and scientific advancements, starting with the focus areas of Artificial Intelligence (AI) and energy.
Under the affiliation agreement, the institute will have office space at the U and will officially be known as the 'Abundance Institute at the University of Utah.'
The U has a rich history of ushering new technology into the world with significant impact. In 1969, it was the fourth node — the first to be located outside of California — on the ARPANET, a Department of Defense project that later evolved into the Internet. Later, the first permanent artificial heart was developed at the U and implanted in a patient. Over the years, many transformative companies have launched with connections to the U, including Blackrock Neurotech, the leader in brain-computer interface technology; Recursion, a $2 billion biotech company that uses AI to find treatments for rare diseases; Adobe, the foremost software company for digital content creation and publication; and Pixar, the award-winning and revolutionary computer animation studio.
The Abundance Institute, led by CEO Christopher Koopman, is a non-profit 501(c)(3) that is dedicated to creating an environment for emerging technologies to grow, develop, and thrive long before they capture the public's attention.
Their work spans various areas, including energy, artificial intelligence, healthcare, and infrastructure. The Abundance Institute collaborates with experts—ranging from technologists to policy researchers—to influence regulations and public perception in ways that support technological breakthroughs.
'I am excited about this partnership,' Koopman said. 'This is not just about how the U can drive the economy of Utah forward, but how does the U shape national conversations about the future.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Moxie and Revision Skincare® Announce Strategic Partnership to Empower High-Growth Medspas
Streamlined Ordering and Exclusive Education Now Available to Moxie-Supported Practices BROOKLYN, N.Y., June 11, 2025 /PRNewswire/ -- Moxie, the growth engine supporting over 400 aesthetic practices nationwide, today announced a strategic partnership with Revision Skincare®, the gold standard in science-backed, clinically proven skincare. This partnership brings Moxie-supported practices direct access to Revision's line of medical grade skincare, streamlined ordering, and elevated educational resources—all designed to drive profitability, operational efficiency, and exceptional client outcomes. "Independent medspas are the heartbeat of our specialty," said Kamau Massey, CEO of Moxie. "By partnering with Revision Skincare, we're expanding the ways in which we give our practices access to elite-tier products and business tools. It's about helping them compete—and win—at the highest level." This collaboration reflects a shared vision: empowering aesthetic entrepreneurs with the kind of brand alignment, service experience, and margin-boosting resources typically reserved for major enterprise clinics. "Our mission has always been to support skincare professionals with advanced innovation and education," said Joe Blahnik, Chief Sales Officer Revision Skincare®. "Moxie's commitment to the success of aesthetic practices mirrors our own—and together, we're making it easier than ever for providers to deliver exceptional results." This partnership is part of Moxie's ongoing commitment to building a best-in-class ecosystem for medspa success—uniting trusted brands that help independent practices grow, differentiate, and deliver exceptional patient experiences. About Moxie Moxie is the aesthetic practice growth and operating engine, helping medspa entrepreneurs reach multimillion dollar growth—with marketing, compliance, coaching, software, and VIP pricing, all in one place. From launch to scale, Moxie powers ambitious injectors and aesthetic entrepreneurs with the infrastructure, strategy, and partnerships they need to win in a competitive industry. About Revision Skincare® Revision Skincare® delivers high-performing, clinically validated skincare formulations rooted in rigorous research and testing. Trusted by professionals in over thirty countries across the globe, their award-winning products are designed to deliver real results—without compromising long-term skin health. Brandi EppolitoHead of MarketingMoxiebrandi@ This release was issued through WebWire®. For more information, visit View original content: SOURCE Moxie Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Community Healthcare Trust Releases 2024 Corporate Sustainability Report
FRANKLIN, Tenn., June 11, 2025 /PRNewswire/ -- Community Healthcare Trust Incorporated (NYSE: CHCT) (the "Company") today announced the release of its second Corporate Sustainability Report highlighting the Company's progress and its sustainability initiatives implemented in 2024. The report is aligned with the Global Reporting Framework Initiative (GRI) and can be found on the Corporate Responsibility page of the Company's Investor Relations section of its website at "From reducing our environmental impact to strengthening our culture of accountability, we are committed to progress that is both meaningful and measurable," said David H. Dupuy, President and Chief Executive Officer of Community Healthcare Trust Incorporated. "This report is not only a reflection of our progress but a reaffirmation of our commitment to transparency and continuous improvement." Key Highlights of the Report: Sustainability initiatives implemented in our corporate office and real estate portfolio Environmental performance of our corporate office and real estate portfolio Progress toward our 2030 environmental targets Climate risk and resiliency policies to identify and manage climate risks Employee, tenant, and community engagement programs Governance practices to ensure transparency, accountability, and ethical conduct About Community Healthcare Trust Incorporated Community Healthcare Trust Incorporated is a real estate investment trust that focuses on owning income-producing real estate properties associated primarily with the delivery of outpatient healthcare services in our target sub-markets throughout the United States. Cautionary Note Regarding Forward-Looking StatementsIn addition to the historical information contained within, the matters discussed in this press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by use of forward-looking terminology such as "believes", "expects", "may", "will," "should", "seeks", "approximately", "intends", "plans", "estimates", "anticipates" or other similar words or expressions, including the negative thereof. Forward-looking statements are based on certain assumptions and can include future expectations, future plans and strategies, financial and operating projections or other forward-looking information. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Because forward-looking statements relate to future events, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the control of Community Healthcare Trust Incorporated (the "Company"). Thus, the Company's actual results and financial condition may differ materially from those indicated in such forward-looking statements. Some factors that might cause such a difference include the following: general volatility of the capital markets and the market price of the Company's common stock, changes in the Company's business strategy, availability, terms and deployment of capital, changes in the real estate industry in general, interest rates or the general economy, adverse developments related to the healthcare industry, changes in governmental regulations, the degree and nature of the Company's competition, the ability to consummate acquisitions under contract, catastrophic or extreme weather and other natural events and the physical effects of climate change, the occurrence of cyber incidents, effects on global and national markets as well as businesses resulting from increased inflation, changes in interest rates, supply chain disruptions, labor conditions, tariffs and global trade tensions, and/or the conflicts in Ukraine and the Middle East, and the other factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's other filings with the Securities and Exchange Commission from time to time. Readers are therefore cautioned not to place undue reliance on the forward-looking statements contained herein which speak only as of the date hereof. The Company intends these forward-looking statements to speak only as of the time of this press release and undertakes no obligation to update forward-looking statements, whether as a result of new information, future developments, or otherwise, except as may be required by law. CONTACT Bill Monroe, 615-771-3052 View original content: SOURCE Community Healthcare Trust Incorporated Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
New paper sheds light on experience of Black prisoners in infamous Stateville prison malaria experiments
Much has been said and written over the years about controversial malaria research conducted on inmates at Illinois' Stateville Penitentiary starting in the 1940s. But at least one part of that story has been largely ignored until now: the role of Black prisoners in that research, which helped lead to the modern practice of using genetic testing to understand how individual patients will react to certain medications, according to the authors of a newly published paper out of the University of Utah. 'We want to highlight the stories of Black prisoners that participated in this prison research in the 1950s onward and give them their due,' said Hannah Allen, a medical ethicist and assistant professor of philosophy at the University of Texas Rio Grande Valley, and first author of the paper, which was published as an opinion piece Wednesday in the Journal of the American Medical Association. 'They haven't been properly acknowledged in the past, and their participation in these studies was really foundational in launching the field of pharmacogenetics and, later on, precision medicine,' said Allen, who recently completed her doctorate at the University of Utah. Starting in the 1940s, researchers infected inmates at the Joliet-area prison with malaria to test the effectiveness of drugs to treat the illness as part of a U.S. military-funded effort to protect American troops overseas, according to the paper. A University of Chicago doctor was the principal investigator. The inmates consented to being part of the studies and were paid for their participation. At first, the research was greeted with enthusiasm. In 1945, Life magazine ran a spread about it, featuring a photo of a Stateville inmate with cups containing malaria-carrying mosquitoes pressed against his bare chest. The first line of the story reads, 'In three U.S. penitentiaries men who have been imprisoned as enemies of society are now helping science fight another enemy of society.' But as the years passed, attitudes began to shift. Questions arose about whether inmates could truly, freely consent to participate in medical experiments or whether they felt coerced into them because of their often dire circumstances. At the Nuremberg trials, defense attorneys for Nazi doctors introduced text and images from the Life article about Stateville prison, though an Illinois physician argued at the trials that the prisoners in Stateville consented to being part of medical research whereas Nazi prisoners did not, according to the JAMA paper. In the mid-1970s, news broke about a study at Tuskegee, in which Black men with syphilis went untreated for years — news that raised awareness of ethical problems in medical research. News outlets also began publishing more stories about prison research, according to the JAMA article. The Chicago Tribune published an article in 1973, in which an inmate participating in the Stateville malaria research said: 'I've been coerced into the project — for the money. Being here has nothing to do with 'doing good for mankind' … I didn't want to keep taking money from my family.' The experiments at Stateville came to a halt in the 1970s. A number of protections and regulations are now in place when it comes to research involving prisoners. Since the 1970s, the Stateville research has often been discussed and analyzed but little attention has been paid to its Black participants, said James Tabery, a medical ethicist and philosophy professor at the University of Utah who led the new research, which was funded by the federal National Institutes of Health. For a time, Black prisoners were excluded from the studies because of a myth that Black people were immune to malaria, Tabery said. Later on, once scientists had pinpointed the drug primaquine as an effective medication for malaria, they turned their attention to the question of why 5% to 10% of Black men experienced a violent reaction to the drug, according to the paper. Ultimately, the scientists were successful, finding that the adverse reaction was related to a specific genetic deficiency. 'There are people all over Chicago today that are getting tested, that clinicians are recommending they get a genetic test before they get prescribed a drug because they want to make sure that their patient isn't going to have an adverse reaction to the drug,' Tabery said. 'It's really sort of powerful and interesting that you can trace that approach to doing good clinical medicine right back to this particular moment and place and population.' But Tabery and Allen also found that the Black prisoners were not treated the same as the white prisoners who participated in research at Stateville. For one, they weren't paid as much as the white prisoners, the rationale being that the white prisoners were infected with malaria, whereas the Black prisoners were given the drug but not infected with the disease — though some of the Black prisoners got very ill after taking the medication, according to the paper. Also, researchers didn't protect the Black participants' privacy as well as they did for other participants. They published certain identifying information about the Black participants, such as initials, ages, heights and weights, whereas participants in the previous research were represented with case numbers, according to the paper. Researchers also recruited the Black prisoners' family members for the study, which they didn't do with earlier participants, according to the paper. 'You see them just doing things with the Black prisoners that they're not doing with the white prisoners,' Tabery said. Also, though scientists made an important discovery through the research on Black prisoners, the episode also highlights the difficulty that can occur in translating discoveries into real life help for patients. Though the World Health Organization now recommends genetic testing to protect people who are sensitive to antimalarials, many of the people who would benefit most from such testing still don't receive it because of financial barriers, supply chain issues and a lack of training, according to the paper. 'What we found is when you sort of shift to what was happening to the Black prisoners, these other lessons you hadn't thought of as being derivable from Stateville suddenly do become apparent,' Tabery said.
